Passage Bio
PASG
44 hedge funds and large institutions have $21.6M invested in Passage Bio in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 9 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0% more funds holding
Funds holding: 44 → 44 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
1.68% less ownership
Funds ownership: 62.6% → 60.92% (-1.7%)
34% less capital inflows, than outflows
Capital inflows: $1.34M | Capital outflows: $2.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$540K |
| 2 |
Morgan Stanley
New York
|
+$520K |
| 3 |
Shay Capital
New York
|
+$86.6K |
| 4 |
Jane Street
New York
|
+$42.9K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$32.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$1.57M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$282K |
| 3 |
Landscape Capital Management
Englewood,
New Jersey
|
-$37.7K |
| 4 |
Two Sigma Investments
New York
|
-$31.7K |
| 5 |
Engineers Gate Manager
New York
|
-$24.3K |
PASG Hedge Fund Activity: Q4 2024 in Review
44 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2024, worth a combined $21.6M — down 20% from $27.1M a quarter earlier.
Fund positioning in PASG was balanced in Q4 2024: 9 funds opened new positions, 9 closed out, 10 added to existing stakes and 9 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $540K. The largest seller was OrbiMed, cutting an estimated $1.57M.
- 44 institutional investors held Passage Bio (PASG) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $21.6M of Passage Bio stock for Q4 2024, down 20% quarter-over-quarter.
- 9 funds opened new Passage Bio positions in Q4 2024 and 9 closed out, a net change of 0 holders.
- The largest Passage Bio buyer in Q4 2024 was Lynx1 Capital Management, an estimated $540K added.
- The largest Passage Bio seller in Q4 2024 was OrbiMed, an estimated $1.57M sold.
Based on aggregated 13F filings for Q4 2024.